TREPPIEDI, DONATELLA
 Distribuzione geografica
Continente #
NA - Nord America 3.029
EU - Europa 2.660
AS - Asia 2.252
SA - Sud America 204
AF - Africa 75
OC - Oceania 9
Totale 8.229
Nazione #
US - Stati Uniti d'America 2.922
DE - Germania 917
CN - Cina 788
SG - Singapore 639
IT - Italia 522
GB - Regno Unito 428
SE - Svezia 205
HK - Hong Kong 181
BD - Bangladesh 180
VN - Vietnam 169
BR - Brasile 153
FR - Francia 113
RU - Federazione Russa 108
NL - Olanda 81
CA - Canada 80
IN - India 77
DK - Danimarca 56
ID - Indonesia 44
FI - Finlandia 43
CI - Costa d'Avorio 41
JP - Giappone 41
IE - Irlanda 39
ES - Italia 33
TR - Turchia 28
KR - Corea 25
AR - Argentina 23
UA - Ucraina 22
MX - Messico 19
BE - Belgio 13
CH - Svizzera 13
PL - Polonia 12
ZA - Sudafrica 12
AT - Austria 11
IQ - Iraq 10
SK - Slovacchia (Repubblica Slovacca) 10
PK - Pakistan 9
AU - Australia 7
RO - Romania 7
EC - Ecuador 6
TW - Taiwan 6
VE - Venezuela 6
CO - Colombia 5
EG - Egitto 5
MY - Malesia 5
NE - Niger 5
PH - Filippine 5
TH - Thailandia 5
BY - Bielorussia 4
IL - Israele 4
NP - Nepal 4
PE - Perù 4
PY - Paraguay 4
SA - Arabia Saudita 4
SC - Seychelles 4
CZ - Repubblica Ceca 3
HR - Croazia 3
HU - Ungheria 3
IR - Iran 3
JO - Giordania 3
KG - Kirghizistan 3
LB - Libano 3
LT - Lituania 3
MA - Marocco 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
CR - Costa Rica 2
DZ - Algeria 2
GT - Guatemala 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
UZ - Uzbekistan 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
HT - Haiti 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SN - Senegal 1
SY - Repubblica araba siriana 1
YE - Yemen 1
Totale 8.229
Città #
Dallas 804
Hanover 659
Southend 373
Singapore 365
Ashburn 325
Chandler 217
Milan 190
San Jose 161
Hong Kong 154
Beijing 115
Frankfurt am Main 97
Ann Arbor 83
New York 83
Santa Clara 76
Council Bluffs 71
Los Angeles 66
Wilmington 63
Fairfield 60
Dearborn 58
Houston 58
Hefei 54
Ho Chi Minh City 48
Seattle 48
Munich 47
Princeton 46
Abidjan 41
Dublin 39
Lauterbourg 39
Buffalo 37
Hanoi 37
Toronto 35
Bengaluru 28
Redwood City 28
Shanghai 28
Woodbridge 28
Hangzhou 24
Cambridge 23
Nanjing 23
Rome 23
Helsinki 22
Jinan 22
Berlin 21
Des Moines 20
São Paulo 20
Guangzhou 19
Jakarta 19
Moscow 19
Seoul 19
Tokyo 19
Istanbul 18
Padova 18
Zhengzhou 18
Columbus 17
Chicago 16
Tianjin 15
Phoenix 14
The Dalles 14
Boardman 13
Montreal 13
Shenyang 12
Córdoba 11
Turin 11
Amsterdam 10
Cangzhou 10
Johannesburg 10
London 10
Naples 10
Haiphong 9
Nanchang 9
Nuremberg 9
Orem 9
Bernolákovo 8
Brussels 8
Da Nang 8
Fremont 8
Hebei 8
Nantong 8
Sevilla 8
Shenzhen 8
Absecon 7
Cinisello Balsamo 7
Grafing 7
Hải Dương 7
Mumbai 7
San Diego 7
Turku 7
Baghdad 6
Brooklyn 6
Changsha 6
Jiaxing 6
Mexico City 6
Ottawa 6
Pittsburgh 6
Plano 6
Wuhan 6
Boston 5
Cagliari 5
Caserta 5
Farmington 5
Florence 5
Totale 5.422
Nome #
AZD1775: effect of monotherapy or EDP-M combination in the treatment of ACC preclinical models 453
Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells 439
Genetic profiling of a cohort of Italian patients with ACTH-secreting pituitary tumors and characterization of a novel USP8 gene variant 428
Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors 415
β-arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors 393
A novel mechanism regulating dopamine receptor type 2 (DRD2) signal transduction in pituitary tumoral cells: the role of cAMP/PKA-induced filamin A (FLNA) phosphorylation 381
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells 380
Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion 375
HIGH-RESOLUTION SPATIOTEMPORAL ANALYSIS OF SOMATOSTATIN RECEPTOR TYPE 2 (SSTR2) - FILAMIN A (FLNA) INTERACTION BY SINGLE-MOLECULE IMAGING 342
IGF2R: a new player in the insulin-like growth factor 2 (IGF2) pathway sustaining adrenocortical carcinoma cells growth 321
Dopamine and somatostatin analogues resistance of pituitary tumors : focus on cytoskeleton involvement 266
Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. 262
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells 243
cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells 243
Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation 241
A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment 232
Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation. 219
Filamin A (FLNA) Plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells 205
Cytoskeleton protein Filamin A is required for efficient Somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells 204
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors 197
Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization 196
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling 184
Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior 181
The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells 179
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs 174
Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation 171
Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues : a systematic review 163
Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas 160
Somatostatin Receptor Type 2 (SSTR2) Internalization and Intracellular Trafficking in Pituitary GH-Secreting Adenomas: Role of Scaffold Proteins and Implications for Pharmacological Resistance 157
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells 137
Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior 106
The novel SST3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells 100
Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer 93
Potential antitumoral effects through modulation of VEGF-A splicing in rat somatotroph and lactotroph pituitary tumoral cells 92
Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells 85
miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects 33
Totale 8.450
Categoria #
all - tutte 20.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.572


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 0 0 0 0 0 0 0 0 35
2021/20221.182 30 43 57 131 156 143 138 108 149 73 27 127
2022/2023612 78 69 52 75 45 113 13 41 56 10 35 25
2023/2024502 25 24 17 36 154 11 52 46 15 40 38 44
2024/20251.144 39 66 21 121 113 65 32 99 68 152 130 238
2025/20263.540 299 886 338 261 226 139 300 101 307 219 377 87
Totale 8.450